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The MMP family is comprised of 25 struc-
turally related zinc-dependent proteinas-
es either secreted into extracellular milieu
or anchored on the cell surface to cleave
extracellular matrix (ECM) molecules
such as collagens, elastins, proteogly-
cans, and glycoproteins (Overall and
Lopez-Otin, 2002; Pei, 1999). While
MMPs have been implicated in diseases
such as arthritis, asthma, atherosclerosis,
and emphysema, it is their role in tumor
invasion and metastasis that has attract-
ed most of the attention. As ECM-degrad-
ing enzymes, the MMPs have been
associated with tumor invasion and
metastasis ever since the discovery of the
first MMP activity in tumor cell-condi-
tioned media. Experimental evidence,
both in vitro and in vivo, has been over-
whelming in proving the causative role of
MMPs in tumor progression (Coussens et
al., 2002). The major debate now is cen-
tered on how MMPs actually mediate
tumor progression. The classic view that
MMPs clear the path for invading tumor
cells remains dominant. An emerging par-
adigm is that MMPs serve as regulators of
the tumor microenvironment, such that
tumor cells gain a proliferative, migratory,
and invasive phenotype by cleaving not
only ECM components, but also pro-
teinase inhibitors, adhesion molecules,
growth factor binding proteins, and a
growing number of cell surface receptor
molecules (Egeblad and Werb, 2002).
The protease-activated receptors,
or PARs, are a family of 4 G protein cou-
pled receptors (GPCRs) sharing the
same mechanism of activation by prote-
olysis. Each PAR carries its own ligand,
which is masked N-terminally at resting
state (Coughlin, 1999; Ossovskaya and
Bunnett, 2004). Many serine proteases,
including thrombin, FXa, FVIIa, trypsin,
tryptase, cathepsin G, MT-SP1, and
plasmin, have been identified as poten-
tial activators for one or more of the
PARs. These proteases can cleave the
scissor bond at R41-S, R34-S, K38-T, or
R47-G in PAR1-4, respectively, to
expose the tethered ligand, which then
binds to the second extracellular loop
on the same receptor and activates it
intramolecularly (see Figure 1). The
activated PARs initiate signal transduc-
tion across the membrane to activate
intracellular G proteins, which regulate
pathways for cell morphology, secre-
tion, cell proliferation, migration, and
adhesion in cells such as platelets, car-
diomyocytes, and smooth muscle cells
under normal physiological conditions
(Ossovskaya and Bunnett, 2004). Since
many of the proteases are released and
activated during tissue damage, the
PARs could serve as sensors for injury
and generate appropriate responses,
like inflammation and wound repair.
Solid tumors can be considered in
many ways as chronic wounds that never
heal (Dvorak, 1986). PARs, especially
PAR1 and PAR2, have also been shown
to be upregulated in malignant tumors in
breast and prostate (Ossovskaya and
Bunnett, 2004). PAR1 in particular has
been shown to be oncogenic in trans-
forming NIH3T3 cells (Whitehead et al.,
1995), and promotes tumor cell invasion
in breast cancer cells (Even-Ram et al.,
1998). Since the tumor microenviron-
ment, like the wounding site, is rich in
proteases, one would have assumed
that thrombin or other serine proteinases
released by tumor, activated stromal,
infiltrating immune, or endothelial cells
were responsible for the activation of
PAR1 on the cancer cell surface.
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Matrix metalloproteinases target protease-activated receptors on
the tumor cell surface
Matrix metalloproteinases, or MMPs, have been implicated in tumor invasion and metastasis by virtue of their ability to
degrade the extracellular matrix (ECM) barrier. However, MMPs are also capable of cleaving non-ECM molecules. The
protease-activated receptors (PARs) are the latest MMP targets. The thrombin receptor PAR1 has now been shown to be
cleaved and activated on the tumor cell surface by stromal-derived MMP1.The resulting PAR1 activates intracellular G pro-
teins to turn on the migratory and invasive program in tumor cells. This MMP-PAR axis may represent a novel signaling
pathway communicating between tumor and stromal cells during tumor progression.
Figure 1. MMP1 activates PAR1 to mediate
tumor cell invasion
Stromal cells synthesize and secrete MMP1 to
the extracellular milieu, where it is activated.
Active MMP1 cleaves type I collagen in the
ECM. MMP1 also binds to and cleaves the
extracellular N terminus of PAR1 to release a
tethered ligand. Upon binding to the second
extracellular loop, the ligand activates the
intracellular G proteins (Gα/β) across the
membrane and initiates a cascade of
events which lead to the invasive pheno-
type for cancer cells.
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A MMP-PAR axis
In a recent issue of Cell, Boire et al.
reported that it is a matrix metallopro-
teinase, MMP1, rather than any of the
serine proteinases, that targets PAR1 on
breast cancer cells to confer a promigra-
tory and proinvasive phenotype (Boire et
al., 2005) (see Figure 1). First, they
showed that MCF-7, a breast cancer cell
line known to be deficient in PAR1 and
noninvasive in vitro and nontumorigenic
in nude mice (Even-Ram et al., 1998),
can be converted into being invasive and
tumorigenic upon the transfection of a
functional PAR1, but not the nonactivat-
ing mutant F43A. Secondly, they demon-
strated that siRNA knockdown of PAR1
in MDA-MB-231 cells rendered them
noninvasive and unable to migrate.
Through proteinase inhibitor profile stud-
ies, they ruled out any role for the known
PAR activators, i.e., the serine proteinas-
es, especially thrombin. Surprisingly,
inhibitors known to inhibit MMPs blocked
both migration and invasion toward the
fibroblast conditioned media, suggesting
that one of the MMPs may be the activa-
tor for PAR1. Eventually, they identified
MMP-1, not MMP-2, -3, -7, or -9, as the
activating proteinase for PAR1 in their
experimental system. Mechanistically,
they demonstrated that MMP-1 directly
triggers PAR1-mediated Ca2+ signals in
MCF7 cells, and both MMP1 inhibitors
and PAR1 antagonists inhibited cell
migration in vitro and tumor growth in
nude mice. Although MMP-1 may turn
out to be the only MMP that can cleave
and activate PAR1, this elegant work cer-
tainly establishes likely MMP/PAR axis
signaling between tumor and stromal
cells (Figure 1).
Into the future
The MMP1/PAR1 story will inspire many
lines of investigations. It would be of
great interest to determine the actual
cleavage site on PAR1 by MMP-1. As a
founding member of the MMP family,
MMP1 has been thoroughly interrogated
by a variety of techniques to define its
specificity. A cleavage at the scissile
bond Arg-Ser, as suggested in PAR1,
has not been identified for MMP-1 so far,
even in a comprehensive search using a
peptide library (Turk et al., 2001). It is
possible that the interaction between
MMP-1 and PAR1 is unique to generate
a novel specificity. Secondly, the active
state of MMP1 in the media conditioned
by stromal fibroblasts should be ana-
lyzed in detail. It is quite surprising that
culture media with 5%–10% fetal bovine
sera contain any freely active MMP1.
One might have assumed that there
would be enough proteinase inhibitors
provided by the sera to quench any
active proteinases. Therefore, it is possi-
ble that MMP1 becomes active upon
interacting with the tumor cell surface, or
even when in contact with PAR1. It would
be exciting to determine how MMP-1
interacts with PAR1 on the cell surface.
PAR1 may turn out to be the long-
sought-after receptor for MMP-1. Finally,
the list of MMPs that may potentially
cleave and activate PAR1, or other
PARs, should be exhausted.
Retrospectively, one may wonder
why the MMP field missed PARs as obvi-
ous targets. First, the cleavage site at R41-
S, R34-S, K38-T, or R47-G in PAR1-4 would
have precluded the consideration of any
MMP as activators, simply because nei-
ther R nor K is known to be favored by the
MMPs immediately amino-terminal to
their cleavage sites. Second, blockade of
tumor cell migration and invasion by
MMP inhibitors has traditionally been
interpreted to be consequence of block-
ing the cleavage of ECM components
bound by the migrating or invading cells
(Coussens et al., 2002). Finally, early bio-
chemical screening for MMP substrates
paid little attention to targets on the cell
surface, perhaps due to inherent difficul-
ties in obtaining and studying membrane
proteins (Pei, 1999). Nevertheless, the
discovery of the MMP-PAR pathway
should encourage a systemic search for
MMP substrates on the tumor cell sur-
face, and perhaps even mark a new
beginning for MMP biology—cell surface
proteolysis. In the meantime, some of the
MMP literature on tumor cell migration
and invasion may be reinterpreted in light
of the MMP-PAR axis. Some of the
observed results may not be due to the
suppression of ECM degradation, but
rather the inhibition of MMP-mediated
PAR1 signaling.
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